New study checks safety of fabry drug in indian patients
NCT ID NCT05067868
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 27 times
Summary
This study looks at how safe Replagal is for children and adults with Fabry disease in India. Five participants will receive the drug every two weeks for about a year. The main goal is to track any side effects or reactions. This is not a cure, but a way to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
All India Institute of Medical Sciences (AIIMS)
RECRUITINGNew Delhi, 110029, India
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Child Health
NOT_YET_RECRUITINGKolkata, 700017, India
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sir Gangaram Hospital
RECRUITINGNew Delhi, 110060, India
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.